Company type | Private |
---|---|
Industry | Biotechnology |
Website | immunexpress.com |
Immunexpress is a private molecular diagnostics company based in Seattle, Washington that is developing products designed to improve the diagnosis of suspected sepsis cases[1]. The Immunexpress technology SeptiCyte quantifies directly from whole blood specific immune response molecular markers that change during a sepsis episode. [2][3]
References
- ^ Venter, D.; Thomas, M.; Lipman, J.; Tang, B.; McLean, A.; Pascoe, R.; Price, G.; Nguyen, T.; Brandon, R.; Sutherland, A. (2010). "A novel molecular biomarker diagnostic for the early detection of sepsis". Critical Care. 14 (Suppl 2): P9. doi:10.1186/cc9112. PMID 25054455.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ Keshavan, Meghana (April 6 2015). “Immunexpress raising $40M; measures immune response to shave sepsis diagnostic time to one hour.” MedCity News.
- ^ Ford, Omar (April 6 2015). “Immunexpress vying for FDA clearance of its sepsis test”. Medical Device Daily